The stark divergence between trailing (103.1x) and forward (30.4x) P/E ratios highlights a market expectation of rapid earnings acceleration; if CTRI delivers this growth, the current price could be justified, but any shortfall would leave investors overpaying relative to peers.
If earnings growth fails to meet the implied ~150% annualized pace, the forward P/E could revert toward the historical average of 25x, causing a potential price decline of roughly 20-30% from current levels, given the existing multiple premium.
| Metric | Historical DCF | Analyst DCF |
|---|---|---|
| Growth Assumption | 2.0% (normalized) (10Y CAGR) | Analyst Rev × 2.2% margin |
| PV of FCF | $251.4M | $379.9M |
| Terminal Value (PV) | $729.6M | $1.36B |
| Enterprise Value | $981.0M | $1.74B |
| Equity Value | $786.4M | $1.55B |
| Implied Stock Price | $11.85 | $23.29 |
| Upside/Downside | -62.0% | -25.4% |
| WACC \ Growth | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 6.2% | $15 | $17 | $19 | $21 | $25 |
| 7.2% | $12 | $13 | $15 | $16 | $18 |
| 8.2% | $10 | $11 | $12 | $13 | $14 |
| 9.2% | $9 | $9 | $10 | $11 | $11 |
| 10.2% | $7 | $8 | $8 | $9 | $9 |
| WACC \ Growth | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 6.2% | $30 | $33 | $37 | $41 | $47 |
| 7.2% | $24 | $26 | $29 | $32 | $35 |
| 8.2% | $20 | $22 | $23 | $25 | $28 |
| 9.2% | $17 | $18 | $20 | $21 | $22 |
| 10.2% | $15 | $16 | $17 | $18 | $19 |
| Method | Implied Value | Upside/Downside | Basis |
|---|---|---|---|
| P/E (Peer) | $9.86 | -68.4% | Peer median P/E (9.6x) × Forward EPS ($1.03) |
| P/B (Peer) | $14.86 | -52.4% | Peer median P/B (1.26x) × Book Value per Share |
| EV/EBITDA (Peer) | $10.41 | -66.6% | Peer median EV/EBITDA (4.9x) × EBITDA - Net Debt |
| P/S (Peer) | $35.74 | +14.5% | Peer median P/S (0.92x) × Revenue per Share |
| DCF | $11.85 | -62.0% | Revenue × FCF Margin projection (normalized FCF) |
| Analyst Target | $35.25 | +12.9% | Consensus of 5 analysts |
This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.
The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.
Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.
Created 2026-06-07 · finexus.net